V-Co Investors Group Acquires 19.9% Stake in Vivos Therapeutics via $2.39M Private Placement, Plans Active Engagement

summarizeSummary

A group of V-Co Investors acquired a 19.9% stake in Vivos Therapeutics through a $2.39 million private placement, providing critical working capital and signaling potential active engagement in the company's strategic direction.

check_boxKey Events

• Significant Capital Infusion

  V-Co Investors 3 LLC invested $2.39 million in Vivos Therapeutics through a private placement, which included the conversion of a $1.4 million convertible promissory note. This capital is designated for general working capital purposes.

• New Major Shareholder Group

  A group of V-Co Investors, managed by SP Manager LLC and Michael C. Skaff, collectively acquired a 19.9% beneficial ownership stake in Vivos Therapeutics as of March 31, 2026.

• Potential for Active Investor Engagement

  The reporting persons stated their intent to engage in discussions with the Issuer's management and board regarding financial performance, strategic direction, operational matters, and corporate governance practices.

• Future Dilution from Warrants

  The private placement included the issuance of common stock purchase warrants and pre-funded warrants, which, if fully exercised, could lead to substantial additional dilution, though a blocker provision limits immediate exercise to prevent ownership exceeding 19.99%.

auto_awesomeAnalysis

This Schedule 13D filing reveals a significant capital infusion for Vivos Therapeutics, a micro-cap company. The $2.39 million private placement, which included the conversion of a $1.4 million convertible note, provides crucial working capital. The V-Co Investors group, now holding a 19.9% beneficial ownership stake, has explicitly stated its intent to engage with management and the board on strategic direction and corporate governance. This indicates a new, influential shareholder group that could drive changes within the company. While the capital raise is positive for the company's financial runway, the substantial dilution from the newly issued shares and potential future dilution from warrants are important considerations for investors.